Chicago Capital LLC lowered its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 8.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,999,740 shares of the biopharmaceutical company’s stock after selling 380,476 shares during the period. Chicago Capital LLC owned 4.77% of Dynavax Technologies worth $22,879,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Dynavax Technologies by 95.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 3,402 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Dynavax Technologies by 148.4% during the 2nd quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 4,445 shares in the last quarter. M&T Bank Corp raised its stake in shares of Dynavax Technologies by 29.5% during the 2nd quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 3,116 shares in the last quarter. Ingalls & Snyder LLC bought a new stake in shares of Dynavax Technologies during the 3rd quarter worth approximately $52,000. Finally, Marshall Wace LLP raised its stake in shares of Dynavax Technologies by 225.0% during the 1st quarter. Marshall Wace LLP now owns 16,449 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 11,387 shares in the last quarter. Institutional investors own 82.40% of the company’s stock.

Shares of DVAX stock traded up $0.16 during trading on Tuesday, reaching $5.78. 970,200 shares of the company’s stock were exchanged, compared to its average volume of 1,002,812. The company has a quick ratio of 4.09, a current ratio of 4.94 and a debt-to-equity ratio of 5.48. The stock has a market capitalization of $471.29 million, a PE ratio of -2.27 and a beta of 0.59. Dynavax Technologies Co. has a twelve month low of $2.60 and a twelve month high of $12.42. The firm’s fifty day moving average price is $6.08 and its 200-day moving average price is $4.67.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). The business had revenue of $10.58 million for the quarter, compared to analyst estimates of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The firm’s revenue was up 624.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.65) earnings per share. As a group, analysts anticipate that Dynavax Technologies Co. will post -2.04 EPS for the current fiscal year.

A number of brokerages have recently issued reports on DVAX. BidaskClub upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. William Blair reiterated a “buy” rating on shares of Dynavax Technologies in a research note on Friday, January 3rd. HC Wainwright reiterated a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Monday. Finally, ValuEngine upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $12.63.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Featured Story: Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.